These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2449084)

  • 41. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
    Dejmek A; Hjerpe A
    Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
    Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J
    J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma.
    Clover J; Oates J; Edwards C
    Histopathology; 1997 Aug; 31(2):140-3. PubMed ID: 9279564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. E-cadherin in mesothelioma.
    Jeffers M
    Hum Pathol; 1996 Nov; 27(11):1245-6. PubMed ID: 8912839
    [No Abstract]   [Full Text] [Related]  

  • 46. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma.
    Shijubo N; Honda Y; Fujishima T; Takahashi H; Kodama T; Kuroki Y; Akino T; Abe S
    Eur Respir J; 1995 Mar; 8(3):403-6. PubMed ID: 7789485
    [TBL] [Abstract][Full Text] [Related]  

  • 47. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
    Edwards C; Oates J
    J Clin Pathol; 1995 Jul; 48(7):626-30. PubMed ID: 7560168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium.
    Marshall RJ; Herbert A; Braye SG; Jones DB
    J Clin Pathol; 1984 Nov; 37(11):1215-21. PubMed ID: 6094617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
    Miettinen M; Sarlomo-Rikala M
    Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.
    Moch H; Oberholzer M; Dalquen P; Wegmann W; Gudat F
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):19-27. PubMed ID: 8212530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Histochemical and biochemical aspects of lectin binding glycoproteins in primary and metastatic adenocarcinoma in the lung.
    Kawai T; Suzuki M
    Mod Pathol; 1994 Feb; 7(2):175-80. PubMed ID: 8008739
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma.
    Whitaker D; Sterrett GF; Shilkin KB
    Pathology; 1982 Jul; 14(3):255-8. PubMed ID: 6290965
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma.
    Sheibani K; Shin SS; Kezirian J; Weiss LM
    Am J Surg Pathol; 1991 Aug; 15(8):779-84. PubMed ID: 2069213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinguishing benign from malignant pleural effusions by lectin immunocytochemistry.
    Rosen-Levin E; Patil JR; Watson CW; Jagirdar J
    Acta Cytol; 1989; 33(4):499-504. PubMed ID: 2473586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. "Thick" cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma.
    Leong AS; Parkinson R; Milios J
    Diagn Cytopathol; 1990; 6(1):9-13. PubMed ID: 2323301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differing lectin-binding patterns of malignant melanoma and nevocellular and Spitz nevi.
    Kohchiyama A; Oka D; Ueki H
    Arch Dermatol Res; 1987; 279(4):226-31. PubMed ID: 3314732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Carcinoembryonic antigen in pleural effusion. Adenocarcinoma versus mesothelioma].
    Supervía A; Guitart AC; Rubio J; Cornudella R
    Rev Clin Esp; 1992 Feb; 190(2):69-71. PubMed ID: 1561440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
    Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
    O'Hara CJ; Corson JM; Pinkus GS; Stahel RA
    Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Keratins in malignant mesotheliomas and pleural adenocarcinomas: comparative immunohistochemical analysis with polyclonal and monoclonal antibodies.
    Bejui-Thivolet F; Patricot LM; Vauzelle JL; Viac J
    Pathol Res Pract; 1984 Sep; 179(1):67-73. PubMed ID: 6209691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.